Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dolutegravir in real life: Self‐reported mental and physical health outcomes after transitioning from efavirenz‐ to dolutegravir‐based antiretroviral therapy in a prospective cohort study in Lesotho

Published:2022-06-22 Issue:2 Volume:24 Page:153-162
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Brown Jennifer A.¹²³^ORCID,Nsakala Bienvenu L.⁴,Mokhele Kuena⁴,Rakuoane Itumeleng⁴,Muhairwe Josephine⁴^ORCID,Glass Tracy R.¹³^ORCID,Amstutz Alain¹³⁵^ORCID,Tschumi Nadine¹³^ORCID,Belus Jennifer M.¹³⁶^ORCID,Klimkait Thomas²³^ORCID,Labhardt Niklaus D.¹³⁵^ORCID

Affiliation:

1. Swiss Tropical and Public Health Institute Basel Switzerland

2. Molecular Virology Group Department of Biomedicine Basel Switzerland

3. University of Basel Basel Switzerland

4. SolidarMed Partnerships for Health Maseru Lesotho

5. University Hospital Basel Basel Switzerland

6. University of Maryland College Park Maryland USA

Funder

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Fondation Botnar

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13352

Reference50 articles.

1. A systematic review of the genetic mechanisms of dolutegravir resistance

2. Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1

3. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

4. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

5. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depression among people living with HIV at a district hospital in KwaZulu-Natal, South Africa;South African Family Practice;2024-04-29

2. Cohort profile: the Viral load Cohort North-East Lesotho (VICONEL) from 2016 to 2022 – cohort description, test volumes, predictors of viraemia, and the road ahead;2024-03-14

3. Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial);JAIDS Journal of Acquired Immune Deficiency Syndromes;2023-11-01

4. Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity;The Journal of Infectious Diseases;2023-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3